Sabine Reinig
For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
Search
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Solidarity with Ukraine
Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations
Do we keep our promise?
Find out from a father-daughter duo how we live up to our new People Promise.
The generalized pustular psoriasis (GPP) Forum 2023
An executive summary of the activities and key takeaways from the GPP Forum 2023
Respimat media
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Anna Race
Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
A lifetime for patients with mental health conditions
Chris Underhill is a social entrepreneur and participant at the Making More Health Convention.
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application